AIxCrypto

Business predictability is very low. Over the past year the company shifted from biotech to crypto/digital‑asset treasury and now to robotics operations. It had zero meaningful revenue through Q2 2026, a six‑month net loss of ~$10.27 million, and disclosed going‑concern risk.

Execution now depends on closing a related‑party acquisition that is non‑binding and on scaling a nascent robot‑sharing model. These are inherently uncertain and capital dependent.